Articles related to ASCO

A study on palliative care for advanced lung cancer patients shows that telehealth can match in-person visits in improving quality of life and patient satisfaction. These findings support the broader implementation of telehealth in oncology.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.